Principal Scientist at Abata Therapeutics

Brisbane, California, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

BiotechnologyIndustries

Requirements

A strong foundation in molecular biology, biochemistry, structural biology, and/or a related field
Ph.D. or M.S. with relevant experience is preferred
Hands-on experience with antibody engineering techniques such as yeast display, phage display, or other directed evolution methods. Experience in library design, build, and validation
Experience in protein purification techniques (including affinity, ion exchange, HIC, SEC) and in chromatography hardware and software (Cytiva AKTA, Agilent HPLC)
Familiarity with antibody binding assays and automating them (ELISA, SPR, FACS)
Proficiency in molecular and cell biology techniques, including mammalian tissue cell culture, and basic skills in molecular biology labs
Excellent analytical and problem-solving skills, with meticulous attention to detail
Strong written and verbal communication skills, with the ability to effectively present complex scientific concepts to both technical and non-technical audiences
Ability to work effectively in a collaborative, multidisciplinary team environment, fostering cooperation and knowledge-sharing among team members

Responsibilities

Closely collaborate with the AI Design and Biology team to identify epitopes of interest, establish binder screening workflow, and optimize molecules for drug discovery
With identified binders: design, express, and test drug-like molecules for functionality to define ideal properties for developmental candidates
Contribute to the preparation of technical reports and presentations
Stay up-to-date with the latest advancements in antibody engineering, protein design, and related fields

Skills

Antibody Engineering

Yeast Display

Phage Display

Directed Evolution

Library Design

Protein Purification

Affinity Chromatography

Ion Exchange Chromatography

HIC

SEC

Cytiva AKTA

Agilent HPLC

ELISA

SPR

FACS

Mammalian Cell Culture

Abata Therapeutics

Develops therapies for autoimmune diseases

About Abata Therapeutics

Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy works by utilizing regulatory T cells to improve patient outcomes. Unlike many competitors, Abata targets a specific niche within the autoimmune disease market and collaborates with partners like ElevateBio for process development and manufacturing. The company's goal is to transform treatment options for autoimmune diseases through advanced research and development.

Cambridge, MassachusettsHeadquarters

2021Year Founded

$184.8MTotal Funding

EARLY_VCCompany Stage

BiotechnologyIndustries

11-50Employees

Risks

Intensifying competition from companies like Sangamo Therapeutics may impact Abata's market share.

Stringent FDA scrutiny on manufacturing could delay Abata's clinical trials.

Rising clinical trial costs pose financial risks to Abata's pipeline progression.

Differentiation

Abata focuses on Treg cell therapies for autoimmune diseases like MS and diabetes.

Their lead product, ABA 201, targets type 1 diabetes with remaining beta cell function.

Abata's strategic partnership with ElevateBio enhances their manufacturing capabilities.

Upsides

Recent investment from Bristol Myers Squibb boosts Abata's Treg therapy pipeline development.

FDA's accelerated approval pathways may expedite Abata's clinical trials.

Growing autoimmune disease prevalence increases demand for Abata's innovative treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free